Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT).

Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT).

Item
http://www.wikidata.org/entity/Q33757126
An integrated approach to defining genetic and environmental determinants for major clinical outcomes involving vitamin D.Plasma renin activity and its association with ischemic heart disease, congestive heart failure, and cerebrovascular disease in a large hypertensive cohort.Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular riskComparing Sodium Intake Strategies in Heart Failure: Rationale and Design of the Prevent Adverse Outcomes in Heart Failure by Limiting Sodium (PROHIBIT) Study.Plasma renin activity and risk of cardiovascular and mortality outcomes among individuals with elevated and nonelevated blood pressureSodium restriction in heart failure: benefit or harm?What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?Plasma renin and cardiovascular risk: what is the evidence for an association?Renin Inhibition with Aliskiren: A Decade of Clinical Experience.Dietary management of heart failure: room for improvement?Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial.The predictability of renin-angiotensin-aldosterone system factors for clinical outcome in patients with acute decompensated heart failure.Blood pressure and plasma renin activity responses to different strategies to inhibit the renin-angiotensin-aldosterone system during exercise.Renin-Angiotensin-Aldosterone System Parameters as Biomarker in Heart Failure Patients With Preserved Ejection Fraction: Focus on Angiotensinogen.Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction
P2860

Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT).

Item
http://www.wikidata.org/entity/Q33757126
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Elevated plasma renin activity ...... eart Failure Trial (Val-HeFT).
@ast
Elevated plasma renin activity ...... eart Failure Trial (Val-HeFT).
@en
type
label
Elevated plasma renin activity ...... eart Failure Trial (Val-HeFT).
@ast
Elevated plasma renin activity ...... eart Failure Trial (Val-HeFT).
@en
prefLabel
Elevated plasma renin activity ...... eart Failure Trial (Val-HeFT).
@ast
Elevated plasma renin activity ...... eart Failure Trial (Val-HeFT).
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Elevated plasma renin activity ...... eart Failure Trial (Val-HeFT).
@en
P2093
P304
P31
P356
10.1016/J.CARDFAIL.2010.06.417
P433
P478
P50
P577
P698
P921